U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06848569) titled 'Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: a Phase II Study' on Feb. 07.
Brief Summary: Study Purpose: To evaluate the efficacy and safety of sintilimab in combination with AVD chemotherapy for the treatment of pediatric and adolescent patients with low-to-intermediate risk classical Hodgkin lymphoma (cHL).
Study Design: This is a prospective, single-arm, multicenter, phase II clinical trial.
Study Population: Pediatric and adolescent patients aged 1 to 18 years, diagnosed with classical Hodgkin lymphoma, and classified as low-to-intermediate risk according to the Ann Arbor staging system.
Treatment Plan...